title: Aliskiren and losartan trial in non-diabetic chronic kidney disease.
abstract: BACKGROUND
  This is a report of a clinical trial on the therapeutic efficacy and safety of combined aliskiren and losartan (an angiotensin II receptor blocker (ARB)) versus aliskiren alone and ARB alone in non-diabetic chronic kidney disease (CKD) over a 3-year period.
  
  
  METHODS
  This was a randomised trial in 155 patients with non-diabetic CKD comparing aliskiren (150 mg/day) (n=52) versus losartan (100 mg/day) (n=52) and the third group aliskiren (150 mg/day) combined with losartan (100 mg/day) (n=51). The trial utilised primary renal end points of eGFR <15 ml/min or end-stage renal failure.
  
  
  RESULTS
  All three groups had significant reduction of proteinuria (p<0.001 for all). The changes in eGFR, total urinary protein from baseline to each year were not significantly different between the three therapeutic groups.
  
  
  CONCLUSIONS
  This study in non-diabetic CKD patients showed that combination therapy with aliskiren and ARB was as efficacious as aliskiren alone and ARB alone. There was one patient who developed a non-fatal stroke in the combined aliskiren and ARB group while the other two groups had none.
authors.affiliation: Department of Renal Medicine, Singapore General Hospital, Singapore woo.keng.thye@sgh.com.sg.
authors.forename: Keng-Thye
authors.initials: KT
authors.lastname: Woo
authors.affiliation: Department of Renal Medicine, Singapore General Hospital, Singapore.
authors.forename: Hui-Lin
authors.initials: HL
authors.lastname: Choong
authors.affiliation: Department of Renal Medicine, Singapore General Hospital, Singapore.
authors.forename: Kok-Seng
authors.initials: KS
authors.lastname: Wong
authors.affiliation: Department of Renal Medicine, Singapore General Hospital, Singapore.
authors.forename: Han-Kim
authors.initials: HK
authors.lastname: Tan
authors.affiliation: Department of Renal Medicine, Singapore General Hospital, Singapore.
authors.forename: Marjorie
authors.initials: M
authors.lastname: Foo
authors.affiliation: Department of Clinical Research, Singapore General Hospital, Singapore.
authors.forename: Stephanie
authors.initials: S
authors.lastname: Fook-Chong
authors.affiliation: Department of Nephrology, National University of Singapore, Singapore.
authors.forename: Evan J C
authors.initials: EJ
authors.lastname: Lee
authors.affiliation: Department of Nephrology, National University of Singapore, Singapore.
authors.forename: Vathsala
authors.initials: V
authors.lastname: Anantharaman
authors.affiliation: Department of Renal Medicine, Singapore General Hospital, Singapore.
authors.forename: Grace S L
authors.initials: GS
authors.lastname: Lee
authors.affiliation: Department of Renal Medicine, Singapore General Hospital, Singapore.
authors.forename: Choong-Meng
authors.initials: CM
authors.lastname: Chan
mesh_terms: D000577:Amides / Q000494:pharmacology / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D015897:Comorbidity; D003710:Demography; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D005650:Fumarates / Q000494:pharmacology / Q000627:therapeutic use*; D005919:Glomerular Filtration Rate; D006801:Humans; D006947:Hyperkalemia / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology; D019808:Losartan / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011507:Proteinuria / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology; D051436:Renal Insufficiency, Chronic / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D013599:Systole / Q000187:drug effects
chemical_list: D000577:Amides; D005650:Fumarates; C446481:aliskiren; D019808:Losartan
keywords: Aliskiren; chronic kidney disease; clinical trial; proteinuria; side effects